Increased survival after gemfibrozil treatment of severe mouse influenza
Identifieur interne : 001452 ( Main/Exploration ); précédent : 001451; suivant : 001453Increased survival after gemfibrozil treatment of severe mouse influenza
Auteurs : Alison Budd [Australie] ; Lisa Alleva [Australie] ; Mohammed Alsharifi [Australie] ; Aulikki Koskinen [Australie] ; Victoria Smythe [Australie] ; Arno Müllbacher [Australie] ; Jeff Wood [Australie] ; Ian Clark [Australie]Source :
- Antimicrobial agents and chemotherapy [ 0066-4804 ] ; 2007.
Descripteurs français
- KwdFr :
- Animaux, Anti-inflammatoires (administration et posologie), Anti-inflammatoires (usage thérapeutique), Gemfibrozil (administration et posologie), Gemfibrozil (usage thérapeutique), Hypolipémiants (administration et posologie), Hypolipémiants (usage thérapeutique), Infections à Orthomyxoviridae (immunologie), Infections à Orthomyxoviridae (mortalité), Infections à Orthomyxoviridae (traitement médicamenteux), Infections à Orthomyxoviridae (virologie), Inflammation (mortalité), Inflammation (traitement médicamenteux), Inflammation (virologie), Résultat thérapeutique, Souris, Souris de lignée BALB C, Sous-type H2N2 du virus de la grippe A (), Sous-type H2N2 du virus de la grippe A (pathogénicité).
- MESH :
- administration et posologie : Anti-inflammatoires, Gemfibrozil, Hypolipémiants.
- immunologie : Infections à Orthomyxoviridae.
- mortalité : Infections à Orthomyxoviridae, Inflammation.
- pathogénicité : Sous-type H2N2 du virus de la grippe A.
- traitement médicamenteux : Infections à Orthomyxoviridae, Inflammation.
- usage thérapeutique : Anti-inflammatoires, Gemfibrozil, Hypolipémiants.
- virologie : Infections à Orthomyxoviridae, Inflammation.
- Pascal (Inist)
English descriptors
- KwdEn :
- Animal, Animals, Anti-Inflammatory Agents (administration & dosage), Anti-Inflammatory Agents (therapeutic use), Antilipemic agent, Gemfibrozil, Gemfibrozil (administration & dosage), Gemfibrozil (therapeutic use), Hypolipidemic Agents (administration & dosage), Hypolipidemic Agents (therapeutic use), Inflammation (drug therapy), Inflammation (mortality), Inflammation (virology), Influenza, Influenza A Virus, H2N2 Subtype (drug effects), Influenza A Virus, H2N2 Subtype (pathogenicity), Mice, Mice, Inbred BALB C, Mouse, Orthomyxoviridae Infections (drug therapy), Orthomyxoviridae Infections (immunology), Orthomyxoviridae Infections (mortality), Orthomyxoviridae Infections (virology), Survival, Treatment, Treatment Outcome.
- MESH :
- chemical , administration & dosage : Anti-Inflammatory Agents, Gemfibrozil, Hypolipidemic Agents.
- chemical , therapeutic use : Anti-Inflammatory Agents, Gemfibrozil, Hypolipidemic Agents.
- drug effects : Influenza A Virus, H2N2 Subtype.
- drug therapy : Inflammation, Orthomyxoviridae Infections.
- immunology : Orthomyxoviridae Infections.
- mortality : Inflammation, Orthomyxoviridae Infections.
- pathogenicity : Influenza A Virus, H2N2 Subtype.
- virology : Inflammation, Orthomyxoviridae Infections.
- Animals, Mice, Mice, Inbred BALB C, Treatment Outcome.
Abstract
Gemfibrozil, an agent that inhibits production of proinflammatory cytokines in addition to its clinically useful lipid-lowering activity, increased survival in BALB/c mice that were already ill from infection by influenza virus A/Japan/305/57 (H2N2). Gemfibrozil was administered intraperitoneally once daily from days 4 to 10 after intranasal exposure to the virus. Survival increased from 26% in vehicle-treated mice (n = 50) to 52% in mice given gemfibrozil at 60 mg/kg/day (n = 46) (P = 0.0026). If this principle translates to patients, a drug already approved for human use, albeit by a different route for another purpose, might be adapted relatively fast for use against influenza, conceivably including human infection with a derivative of the avian H5N1 strain.
Url:
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000038
- to stream PascalFrancis, to step Curation: 000036
- to stream PascalFrancis, to step Checkpoint: 000036
- to stream Main, to step Merge: 001471
- to stream Pmc, to step Corpus: 000263
- to stream Pmc, to step Curation: 000263
- to stream Pmc, to step Checkpoint: 000B61
- to stream PubMed, to step Corpus: 000281
- to stream PubMed, to step Curation: 000281
- to stream PubMed, to step Checkpoint: 000258
- to stream Ncbi, to step Merge: 000228
- to stream Ncbi, to step Curation: 000228
- to stream Ncbi, to step Checkpoint: 000228
- to stream Main, to step Merge: 001391
- to stream Main, to step Curation: 001452
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Increased survival after gemfibrozil treatment of severe mouse influenza</title><author><name sortKey="Budd, Alison" sort="Budd, Alison" uniqKey="Budd A" first="Alison" last="Budd">Alison Budd</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>School of Biochemistry and Molecular Biology, Australian National University</s1><s2>Canberra ACT 0200</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Canberra ACT 0200</wicri:noRegion></affiliation></author><author><name sortKey="Alleva, Lisa" sort="Alleva, Lisa" uniqKey="Alleva L" first="Lisa" last="Alleva">Lisa Alleva</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>School of Biochemistry and Molecular Biology, Australian National University</s1><s2>Canberra ACT 0200</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Canberra ACT 0200</wicri:noRegion></affiliation></author><author><name sortKey="Alsharifi, Mohammed" sort="Alsharifi, Mohammed" uniqKey="Alsharifi M" first="Mohammed" last="Alsharifi">Mohammed Alsharifi</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>John Curtin School of Medical Research, Australian National University</s1><s2>Canberra ACT 0200</s2><s3>AUS</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Canberra ACT 0200</wicri:noRegion></affiliation></author><author><name sortKey="Koskinen, Aulikki" sort="Koskinen, Aulikki" uniqKey="Koskinen A" first="Aulikki" last="Koskinen">Aulikki Koskinen</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>John Curtin School of Medical Research, Australian National University</s1><s2>Canberra ACT 0200</s2><s3>AUS</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Canberra ACT 0200</wicri:noRegion></affiliation></author><author><name sortKey="Smythe, Victoria" sort="Smythe, Victoria" uniqKey="Smythe V" first="Victoria" last="Smythe">Victoria Smythe</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>John Curtin School of Medical Research, Australian National University</s1><s2>Canberra ACT 0200</s2><s3>AUS</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Canberra ACT 0200</wicri:noRegion></affiliation></author><author><name sortKey="Mullbacher, Arno" sort="Mullbacher, Arno" uniqKey="Mullbacher A" first="Arno" last="Müllbacher">Arno Müllbacher</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>John Curtin School of Medical Research, Australian National University</s1><s2>Canberra ACT 0200</s2><s3>AUS</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Canberra ACT 0200</wicri:noRegion></affiliation></author><author><name sortKey="Wood, Jeff" sort="Wood, Jeff" uniqKey="Wood J" first="Jeff" last="Wood">Jeff Wood</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Statistical Consulting Unit, Australian National University</s1><s2>Canberra ACT 0200</s2><s3>AUS</s3><sZ>7 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Canberra ACT 0200</wicri:noRegion></affiliation></author><author><name sortKey="Clark, Ian" sort="Clark, Ian" uniqKey="Clark I" first="Ian" last="Clark">Ian Clark</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>School of Biochemistry and Molecular Biology, Australian National University</s1><s2>Canberra ACT 0200</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Canberra ACT 0200</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">07-0400150</idno><date when="2007">2007</date><idno type="stanalyst">PASCAL 07-0400150 INIST</idno><idno type="RBID">Pascal:07-0400150</idno><idno type="wicri:Area/PascalFrancis/Corpus">000038</idno><idno type="wicri:Area/PascalFrancis/Curation">000036</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000036</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000036</idno><idno type="wicri:doubleKey">0066-4804:2007:Budd A:increased:survival:after</idno><idno type="wicri:Area/Main/Merge">001471</idno><idno type="wicri:source">PMC</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1932503</idno><idno type="RBID">PMC:1932503</idno><idno type="wicri:Area/Pmc/Corpus">000263</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000263</idno><idno type="wicri:Area/Pmc/Curation">000263</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000263</idno><idno type="wicri:Area/Pmc/Checkpoint">000B61</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000B61</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:17562808</idno><idno type="wicri:Area/PubMed/Corpus">000281</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000281</idno><idno type="wicri:Area/PubMed/Curation">000281</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000281</idno><idno type="wicri:Area/PubMed/Checkpoint">000258</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000258</idno><idno type="wicri:Area/Ncbi/Merge">000228</idno><idno type="wicri:Area/Ncbi/Curation">000228</idno><idno type="wicri:Area/Ncbi/Checkpoint">000228</idno><idno type="wicri:doubleKey">0066-4804:2007:Budd A:increased:survival:after</idno><idno type="wicri:Area/Main/Merge">001391</idno><idno type="wicri:Area/Main/Curation">001452</idno><idno type="wicri:Area/Main/Exploration">001452</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Increased survival after gemfibrozil treatment of severe mouse influenza</title><author><name sortKey="Budd, Alison" sort="Budd, Alison" uniqKey="Budd A" first="Alison" last="Budd">Alison Budd</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>School of Biochemistry and Molecular Biology, Australian National University</s1><s2>Canberra ACT 0200</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Canberra ACT 0200</wicri:noRegion></affiliation></author><author><name sortKey="Alleva, Lisa" sort="Alleva, Lisa" uniqKey="Alleva L" first="Lisa" last="Alleva">Lisa Alleva</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>School of Biochemistry and Molecular Biology, Australian National University</s1><s2>Canberra ACT 0200</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Canberra ACT 0200</wicri:noRegion></affiliation></author><author><name sortKey="Alsharifi, Mohammed" sort="Alsharifi, Mohammed" uniqKey="Alsharifi M" first="Mohammed" last="Alsharifi">Mohammed Alsharifi</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>John Curtin School of Medical Research, Australian National University</s1><s2>Canberra ACT 0200</s2><s3>AUS</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Canberra ACT 0200</wicri:noRegion></affiliation></author><author><name sortKey="Koskinen, Aulikki" sort="Koskinen, Aulikki" uniqKey="Koskinen A" first="Aulikki" last="Koskinen">Aulikki Koskinen</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>John Curtin School of Medical Research, Australian National University</s1><s2>Canberra ACT 0200</s2><s3>AUS</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Canberra ACT 0200</wicri:noRegion></affiliation></author><author><name sortKey="Smythe, Victoria" sort="Smythe, Victoria" uniqKey="Smythe V" first="Victoria" last="Smythe">Victoria Smythe</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>John Curtin School of Medical Research, Australian National University</s1><s2>Canberra ACT 0200</s2><s3>AUS</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Canberra ACT 0200</wicri:noRegion></affiliation></author><author><name sortKey="Mullbacher, Arno" sort="Mullbacher, Arno" uniqKey="Mullbacher A" first="Arno" last="Müllbacher">Arno Müllbacher</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>John Curtin School of Medical Research, Australian National University</s1><s2>Canberra ACT 0200</s2><s3>AUS</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Canberra ACT 0200</wicri:noRegion></affiliation></author><author><name sortKey="Wood, Jeff" sort="Wood, Jeff" uniqKey="Wood J" first="Jeff" last="Wood">Jeff Wood</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Statistical Consulting Unit, Australian National University</s1><s2>Canberra ACT 0200</s2><s3>AUS</s3><sZ>7 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Canberra ACT 0200</wicri:noRegion></affiliation></author><author><name sortKey="Clark, Ian" sort="Clark, Ian" uniqKey="Clark I" first="Ian" last="Clark">Ian Clark</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>School of Biochemistry and Molecular Biology, Australian National University</s1><s2>Canberra ACT 0200</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Canberra ACT 0200</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">Antimicrobial agents and chemotherapy</title><title level="j" type="abbreviated">Antimicrob. agents chemother.</title><idno type="ISSN">0066-4804</idno><imprint><date when="2007">2007</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Antimicrobial agents and chemotherapy</title><title level="j" type="abbreviated">Antimicrob. agents chemother.</title><idno type="ISSN">0066-4804</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animal</term><term>Animals</term><term>Anti-Inflammatory Agents (administration & dosage)</term><term>Anti-Inflammatory Agents (therapeutic use)</term><term>Antilipemic agent</term><term>Gemfibrozil</term><term>Gemfibrozil (administration & dosage)</term><term>Gemfibrozil (therapeutic use)</term><term>Hypolipidemic Agents (administration & dosage)</term><term>Hypolipidemic Agents (therapeutic use)</term><term>Inflammation (drug therapy)</term><term>Inflammation (mortality)</term><term>Inflammation (virology)</term><term>Influenza</term><term>Influenza A Virus, H2N2 Subtype (drug effects)</term><term>Influenza A Virus, H2N2 Subtype (pathogenicity)</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Mouse</term><term>Orthomyxoviridae Infections (drug therapy)</term><term>Orthomyxoviridae Infections (immunology)</term><term>Orthomyxoviridae Infections (mortality)</term><term>Orthomyxoviridae Infections (virology)</term><term>Survival</term><term>Treatment</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Anti-inflammatoires (administration et posologie)</term><term>Anti-inflammatoires (usage thérapeutique)</term><term>Gemfibrozil (administration et posologie)</term><term>Gemfibrozil (usage thérapeutique)</term><term>Hypolipémiants (administration et posologie)</term><term>Hypolipémiants (usage thérapeutique)</term><term>Infections à Orthomyxoviridae (immunologie)</term><term>Infections à Orthomyxoviridae (mortalité)</term><term>Infections à Orthomyxoviridae (traitement médicamenteux)</term><term>Infections à Orthomyxoviridae (virologie)</term><term>Inflammation (mortalité)</term><term>Inflammation (traitement médicamenteux)</term><term>Inflammation (virologie)</term><term>Résultat thérapeutique</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Sous-type H2N2 du virus de la grippe A ()</term><term>Sous-type H2N2 du virus de la grippe A (pathogénicité)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anti-Inflammatory Agents</term><term>Gemfibrozil</term><term>Hypolipidemic Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Inflammatory Agents</term><term>Gemfibrozil</term><term>Hypolipidemic Agents</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Anti-inflammatoires</term><term>Gemfibrozil</term><term>Hypolipémiants</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Influenza A Virus, H2N2 Subtype</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Inflammation</term><term>Orthomyxoviridae Infections</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Infections à Orthomyxoviridae</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Orthomyxoviridae Infections</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Inflammation</term><term>Orthomyxoviridae Infections</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Infections à Orthomyxoviridae</term><term>Inflammation</term></keywords><keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Influenza A Virus, H2N2 Subtype</term></keywords><keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>Sous-type H2N2 du virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à Orthomyxoviridae</term><term>Inflammation</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anti-inflammatoires</term><term>Gemfibrozil</term><term>Hypolipémiants</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à Orthomyxoviridae</term><term>Inflammation</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Inflammation</term><term>Orthomyxoviridae Infections</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Treatment Outcome</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Animaux</term><term>Résultat thérapeutique</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Sous-type H2N2 du virus de la grippe A</term><term>Survie</term><term>Gemfibrozil</term><term>Traitement</term><term>Animal</term><term>Souris</term><term>Grippe</term><term>Hypolipémiant</term><term>Forme grave</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Gemfibrozil, an agent that inhibits production of proinflammatory cytokines in addition to its clinically useful lipid-lowering activity, increased survival in BALB/c mice that were already ill from infection by influenza virus A/Japan/305/57 (H2N2). Gemfibrozil was administered intraperitoneally once daily from days 4 to 10 after intranasal exposure to the virus. Survival increased from 26% in vehicle-treated mice (n = 50) to 52% in mice given gemfibrozil at 60 mg/kg/day (n = 46) (P = 0.0026). If this principle translates to patients, a drug already approved for human use, albeit by a different route for another purpose, might be adapted relatively fast for use against influenza, conceivably including human infection with a derivative of the avian H5N1 strain.</div></front></TEI><affiliations><list><country><li>Australie</li></country></list><tree><country name="Australie"><noRegion><name sortKey="Budd, Alison" sort="Budd, Alison" uniqKey="Budd A" first="Alison" last="Budd">Alison Budd</name></noRegion><name sortKey="Alleva, Lisa" sort="Alleva, Lisa" uniqKey="Alleva L" first="Lisa" last="Alleva">Lisa Alleva</name><name sortKey="Alsharifi, Mohammed" sort="Alsharifi, Mohammed" uniqKey="Alsharifi M" first="Mohammed" last="Alsharifi">Mohammed Alsharifi</name><name sortKey="Clark, Ian" sort="Clark, Ian" uniqKey="Clark I" first="Ian" last="Clark">Ian Clark</name><name sortKey="Koskinen, Aulikki" sort="Koskinen, Aulikki" uniqKey="Koskinen A" first="Aulikki" last="Koskinen">Aulikki Koskinen</name><name sortKey="Mullbacher, Arno" sort="Mullbacher, Arno" uniqKey="Mullbacher A" first="Arno" last="Müllbacher">Arno Müllbacher</name><name sortKey="Smythe, Victoria" sort="Smythe, Victoria" uniqKey="Smythe V" first="Victoria" last="Smythe">Victoria Smythe</name><name sortKey="Wood, Jeff" sort="Wood, Jeff" uniqKey="Wood J" first="Jeff" last="Wood">Jeff Wood</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001452 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001452 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:07-0400150
|texte= Increased survival after gemfibrozil treatment of severe mouse influenza
}}
| This area was generated with Dilib version V0.6.33. |  |